ICTRP Search Portal

Main

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.

Register:	JPRN
Last refreshed on:	17 October 2023
Main ID:	JPRN-UMIN000015823
Date of registration:	05/12/2014
Prospective Registration:	No
Primary sponsor:	University of Yamanashi
Public title:	Switching from latanoprost or travoprost ophthalmolic solution to tafruprost and timolol fixed ophthalmic solution
Scientific title:	Switching from latanoprost or travoprost ophthalmolic solution to tafruprost and timolol fixed ophthalmic solution - Switching from latanoprost or travoprost to tafruprost and timolol fixed ophthalmic solution
Date of first enrolment:	2014/12/01
Target sample size:	40
Recruitment status:	Complete: follow-up complete
URL:	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018087
Study type:	Interventional
Study design:	Single arm Non-randomized
Phase:	Not selected

Countries of recruitment
Japan

Contacts

Name:	Kenji Kashiwagi
Address:	1110 Shimokato Chuo Yamanashi Japan
Telephone:	055-273-1111
Email:	kenjik@yamanashi.ac.jp
Affiliation:	University of Yamanashi Ophthalmology

Name:	Kenji Kashiwagi
Address:	1110 Shimokato Chuo Yamanashi Japan
Telephone:	055-273-1111
Email:	kenjik@yamanashi.ac.jp
Affiliation:	University of Yamanashi Ophthalmology

Key inclusion & exclusion criteria

Inclusion criteria:
Exclusion criteria: Severe respiratory diseases Severe systemic diseases Allegic reaction against contents of the experimental compounds

Age minimum: 20years-old
Age maximum: Not applicable
Gender: Male and Female

Health Condition(s) or Problem(s) studied

Primary open angle glaucoma and ocular hypertension

Intervention(s)

Switching from latanoprost or travoprost monotherapy to tafluprost/timolol fixed combination

Primary Outcome(s)

Reduction of intraocular pressure Topical and systemic adverse effects

Secondary Outcome(s)

Secondary ID(s)

Source(s) of Monetary Support

Santen Pharmaceitical Co. Ltd

Secondary Sponsor(s)

Ethics review

Status: YES
Approval date:
Contact:

Results

Results available:	Yes
Date Posted:
Date Completed:	29/02/2016
URL:

Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.